INTERCEPT is not approved for sale in the United States and certain other countries.

SIGN UP FOR OUR
E-NEWSLETTER

INTERCEPT eNews delivers product news & information updates.

2003

2003 INTERCEPT Conference Abstracts

 

Jump to Conference
ASBMT ISATS ESP ISFA
PAS SFTS ESFH AABB
ISPOR ISBT ICAAC NHF
EHA ISTH DGTI ASH
NATA EBMT IDSA  

 

American Society for Blood and Marrow Transplantation (ASBMT)
January 2003 | Keystone, Colorado, USA
 

  • Lin L, Corash L. Prevention of platelet TA-GVHD by use of INTERCEPT Blood System.

Pediatric Academic Societies' Annual Meeting (PAS)
May 2003 | Seattle, Washington, USA

  • Strauss R, Eastlund D, Lopez-Plaza I et al. INTERCEPT Platelets provided effective hemostasis in thrombocytopenic children: Results of the SPRINT trial.

8th Annual Intercontinental Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 2003 | Arlington, Virginia, USA 

  • Gao X, Botteman MF, Weissfeld JL et al. Cost-effectiveness of transfusing platelet components prepared with pathogen inactivation treatment in orthopedic surgery in the United States.

8th Congress of the European Hematology Association (EHA)
June 2003 | Lyon, France
 

  • Sawyer L, Dupuis K, Alfonso R et al. The INTERCEPT Blood System for platelets inactivates high titers of a variety of blood-borne pathogens in platelets.
     
  • Ciaravino V, McCullough T, Sullivan T. The lack of toxicity in a 3-month dog study administered autologous platelets treated with the INTERCEPT Blood System.

Network for Advancement of Transfusion Alternatives First North American Symposium (NATA)
June 2003 | San Francisco, California, USA
    

  • Sawyer L, Dupuis K, Alfonso R et al. Helinx technology, used in the INTERCEPT Blood System, inactivates emerging insect-borne pathogens in platelets, plasma, and red blood cells.

International Symposium on Advances in Transfusion Safety (ISATS)
June 2003 | Bethesda, Maryland, USA 

  • Ciaravino V, McCullough T. Pharmacokinetic and toxicology assessment of photochemically-treated platelets: No toxicologically relevant effects.
     
  • Conlan M, Flament J. Helinx-treated platelets provide effective hemostasis and count increments: Comparison to conventional platelets in 2 Phase 3 clinical trials.
     
  • Conlan M, Lin J-S, Flament J et al. Platelets treated with Helinx technology to inactivate pathogens and contaminating T-cells prevented Transfusion-Associated Graft vs. Host Disease (TA-GVHD): Results of 3 clinical trials.
     
  • Dupuis K, Alfonso R, Savoor A et al. Helinx technology inactivates high titers of a variety of emerging blood-borne pathogens in platelets.

XXI Congres de la Societe Francaise de Transfusion Sanguine (SFTS)
June 2003 | Saint-Etienne, France
 

  • Ciaravino V, Payrat JM. Pharmacokinetic and toxicology assessment of INTERCEPT Platelets: No toxicologically relevant effects.
     
  • Dupuis K, Alfonso R, Grellier P et al. The INTERCEPT Blood System for platelet concentrates inactivates Plasmodium falciparum.
     
  • Dupuis K, Alfonso R, Guilleman B et al. The INTERCEPT Blood System for platelet concentrates inactivates Human T-cell Lymphotropic Virus Types I and II (HTLV-I & -II).
     
  • Dupuis K, Alfonso R, Hanson D et al. Helinx technology inactivates high titers of transfusion-transmitted pathogens in platelets.

8th Regional European Congress of the International Society of Blood Transfusion (ISBT)
July 2003 | Istanbul, Turkey
 

  • Ciaravino V, McCullough T, Sullivan T et al. No toxicity observed in a 3-month study in beagle dogs administered autologous platelets treated with the INTERCEPT Blood System.
     
  • Conlan M, Lin J-S, Flament J et al. INTERCEPT Platelets treated with Helinx technology to inactivate T-cells prevented Transfusion-Associated Graft vs. Host Disease (TA-GVHD): Results of 3 clinical trials.
     
  • Dupuis K, Alfonso R, Savoor A et al. Helinx technology, used in the INTERCEPT Blood System, inactivates high titers of emerging insect-borne pathogens in platelets and red cells.
     
  • Snyder E, Slichter S, McCullough J et al. INTERCEPT Platelets provided acceptable therapeutic responses during multiple transfusion cycles: The SPRINT Trial.

19th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
July 2003 | Birmingham, UK
 

  • Ciaravino V, Cimino G, McCullough T. Preclinical safety assessment of photochemically-treated platelets: No toxicologically relevant effects with large multiples of the clinical exposure.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT)
July 2003 | Istanbul, Turkey
  

  • Sullivan T, Ciaravino V, McCullough T. No clinically relevant toxicity shown in the preclinical safety assessment of the INTERCEPT Blood System for platelets.
     
  • Conlan M, Lin J-S, Flament J et al. INTERCEPT Platelets treated with Helinx technology to inactivate T-cells prevented Transfusion-Associated Graft vs. Host Disease (TA-GVHD): Results of 3 clinical trials.

10th Annual Congress of the European Society for Photobiology (ESP)
September 2003 | Vienna, Austria
 

  • Hearst JE. Psoralen from lab bench, through clinical trials, to the market.

14th Congress of the European Society for Haemapheresis and Haemotherapy (ESFH)
September 2003 | Prague, Czech Republic 

  • Conlan M. The INTERCEPT Blood System for platelets provides pathogen inactivation while maintaining platelet therapeutic efficacy.

43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 2003 | Chicago, Illinois, USA

  • Sawyer L, Dupuis K, Bernard K et al. Helinx technology inactivates high titers of a variety of blood-borne pathogens in platelets.

36th Congress of the Deutsche Gesellschaft für Transfusionsmedizin und Immunhümatologie (DGTI)
September 2003 | Innsbruck, Austria
 

  • Dupuis K, Sampson-Johannes A, Corash L. The INTERCEPT Blood System for platelets inactivates the causative agent of SARS.

41st Annual Meeting of the Infectious Diseases Society of America (IDSA)
October 2003 | San Diego, California, USA
 

  • Van Voohis W, Barrett L, Eastman R et al. Inactivation of Trypanosoma cruzi and Leishmania mexicana in human platelet concentrates and plasma by amotosalen HCl and UVA illumination.

4th World Congress of the International Society for Apheresis (ISFA)
November 2003 | Nashville, Tennessee, USA 

 

  • Donnelly B, Bartram M, Chen D et al. INTERCEPT Platelets treated for pathogen inactivation from Haemonetics MCS+ and Cobe Spectra Systems are similar to Amicus Separator and meet AABB standards.
     
  • Donnelly B, Bartram M, Murphey R et al. INTERCEPT Platelets treated for pathogen inactivation from Trima Collection System are similar to Amicus Separator and meet AABB standards.

56th Annual Meeting of the American Association of Blood Banks (AABB)
November 2003 | San Diego, California, USA
  

  • Benjamin R, Goodnough L, Lopez-Plaza I et al. Fresh (1-2 day-old) vs. aged (4-5 day-old) INTERCEPT platelets and conventional platelets provide comparable count increments, however, fresh platelets result in superior hemostasis: results of the SPRINT trial.
     
  • Bernard K, Jones S, Dupuis K. West Nile Virus is inactivated by Helinx technology in human platelet concentrates.
     
  • Ciaravino V, Sullivan T, McCullough T. The absence of reproductive toxicity demonstrated by the INTERCEPT Blood System for platelets.
  • Donnelly B, Chen A, Blair A et al. INTERCEPT Platelets from Haemonetics MCS+ and Cobe Spectra Systems demonstrate inactivation of key pathogens, retain function, and meet AABB standards.
     
  • Donnelly B, Taga T, Murphey R et al. INTERCEPT Platelets from Trima Collection System retain function, demonstrate inactivation of key pathogens, and meet AABB standards.
     
  • Lin L, Porter S, Lin J-S, Conlan M. Multiple transfusions of platelet concentrates treated with amotosalen and UVA for pathogen inactivation did not result in amotosalen accumulation in patient plasma.
     
  • Lopez-Plaza I, Snyder E, Goodnough L et al. INTERCEPT platelet transfusions are associated with fewer transfusion reactions than conventional platelet transfusions prepared by apheresis with process leukoreduction.
     
  • Rentas F, Lippert L, Harman R et al. Inactivation of Orienta tsutsugamuchi in an animal model using the INTERCEPT Blood System for platelets.
     
  • Sampson-Johannes A, Sawyer L. Helinx technology inactivates vaccinia virus in human platelet concentrates.

National Hemophilia Foundation's 55th Annual Meeting (NHF)
November 2003 | Salt Lake City, Utah, USA

  • Sawyer L, Dupuis K, Sampson-Johannes A et al. Helinx technology inactivates hight titers of traditional and emerging viruses in platelet concentrates and plasma.

American Society of Hematology 45th Annual Meeting and Exposition (ASH)
December 2003 | San Diego, California, USA
  

  • Bruchmüller I, Janetzko K, Bugert P et al. Use of a PCR inhibition assay to monitor the photochemical pathogen inactivation process by Helinx technology is feasible.
     
  • Dupuis K, Sampson-Johannes A. The causative agent of SARS in platelet and red cell concentrates is inactivated by Helinx technology.
     
  • Murphy S, Snyder E, Cable R et al. Transfusion of INTERCEPT platelets vs. reference platelets at doses ≥3.0x1011 results in comparable hemostasis and platelet and RBC transfusion requirements: Results of the SPRINT trial.
Untitled Document